BioTuesdays

Category - Feature

Feature

OnPoint’s Big-Data Equals Big Opportunity

By Len Zehr OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with...

April 16, 2013
Feature

DURECT awaiting Pfizer meeting with FDA on Remoxy

By Len Zehr DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper...

February 26, 2013
Feature

In conversation with Will Zerhouni

By Len Zehr As CEO of closely held i3 Analytics, Will Zerhouni founded the company on the belief that data analytics should be for everyone in biopharma, not just major players with deep pockets. As a former associate...

February 5, 2013
Feature

Prima BioMed to get key CVac data in second half

By Len Zehr After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its...

January 29, 2013
Feature

Trimel in pre-NDA meeting with FDA next month

By Len Zehr Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug...

January 15, 2013